SMT202000643T1 - Anticorpi anti-attivina a e loro usi - Google Patents

Anticorpi anti-attivina a e loro usi

Info

Publication number: SMT202000643T1
Authority: SM; San Marino
Prior art keywords: activin; antibodies
Prior art date: 2013-07-30

Application number

SM20200643T

Other languages

English (en)

Inventor

Andrew J Murphy

Esther Latres

George D Yancopoulos

Jesper Gromada

Lori C Morton

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-07-30

Filing date

2014-07-30

Publication date

2021-01-05

2014-07-30 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2021-01-05 Publication of SMT202000643T1 publication Critical patent/SMT202000643T1/it

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Immunology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

SM20200643T 2013-07-30 2014-07-30 Anticorpi anti-attivina a e loro usi SMT202000643T1 (it)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US201361859926P	2013-07-30	2013-07-30
US201361864036P	2013-08-09	2013-08-09
US201361911834P	2013-12-04	2013-12-04
US201361913885P	2013-12-09	2013-12-09
EP14750421.1A EP3027209B1 (en)	2013-07-30	2014-07-30	Anti-activin a antibodies and uses thereof
PCT/US2014/048957 WO2015017576A1 (en)	2013-07-30	2014-07-30	Anti-activin a antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
SMT202000643T1 true SMT202000643T1 (it)	2021-01-05

Family

ID=52427866

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM20200643T SMT202000643T1 (it)	2013-07-30	2014-07-30	Anticorpi anti-attivina a e loro usi

Country Status (28)

Country	Link
US (4)	US9718881B2 (it)
EP (4)	EP4062937A1 (it)
JP (6)	JP6581085B2 (it)
KR (2)	KR102440044B1 (it)
CN (2)	CN113845594A (it)
AU (2)	AU2014296243B2 (it)
BR (1)	BR112016002164B1 (it)
CA (1)	CA2920071C (it)
CL (1)	CL2016000251A1 (it)
CY (1)	CY1123788T1 (it)
DK (1)	DK3027209T3 (it)
EA (1)	EA037926B1 (it)
ES (1)	ES2827673T3 (it)
HR (1)	HRP20201729T1 (it)
HU (1)	HUE052518T2 (it)
IL (2)	IL243822B (it)
LT (1)	LT3027209T (it)
MX (2)	MX371498B (it)
PH (1)	PH12016500182B1 (it)
PT (1)	PT3027209T (it)
RS (1)	RS61124B1 (it)
SG (1)	SG11201600731WA (it)
SI (1)	SI3027209T1 (it)
SM (1)	SMT202000643T1 (it)
TW (2)	TWI655207B (it)
UY (1)	UY35682A (it)
WO (1)	WO2015017576A1 (it)
ZA (1)	ZA201601294B (it)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
BRPI0618947B1 (pt)	2005-11-23	2022-07-19	Acceleron Pharma Inc	Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
CL2007002567A1 (es)	2006-09-08	2008-02-01	Amgen Inc	Proteinas aisladas de enlace a activina a humana.
US8895016B2 (en)	2006-12-18	2014-11-25	Acceleron Pharma, Inc.	Antagonists of activin-actriia and uses for increasing red blood cell levels
TWI584815B (zh)	2007-02-01	2017-06-01	艾瑟勒朗法瑪公司	活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
TW201627320A (zh)	2007-02-02	2016-08-01	艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
MX2009008510A (es)	2007-02-09	2010-01-15	Acceleron Pharma Inc	Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
CA2699936A1 (en)	2007-09-18	2009-03-26	Acceleron Pharma Inc.	Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
DK3750552T5 (da)	2008-08-14	2024-08-26	Acceleron Pharma Inc	Gdf-fælder
CN107267520A (zh)	2009-06-12	2017-10-20	阿塞勒隆制药公司	截短的actriib‑fc融合蛋白
ES2658292T3 (es)	2009-11-17	2018-03-09	Acceleron Pharma, Inc.	Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
JO3340B1 (ar)	2010-05-26	2019-03-13	Regeneron Pharma	مضادات حيوية لـعامل تمايز النمو 8 البشري
CA2817008A1 (en)	2010-11-08	2012-05-18	Acceleron Pharma Inc.	Actriia binding agents and uses thereof
SMT201800092T1 (it)	2011-11-14	2018-03-08	Regeneron Pharma	Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
RU2678117C2 (ru)	2012-11-02	2019-01-23	Селджин Корпорейшн	Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
TWI655207B (zh) *	2013-07-30	2019-04-01	再生元醫藥公司	抗活化素ａ之抗體及其用途
CN114699529A (zh)	2014-06-13	2022-07-05	阿塞勒隆制药公司	用于治疗溃疡的方法和组合物
US20160075772A1 (en) *	2014-09-12	2016-03-17	Regeneron Pharmaceuticals, Inc.	Treatment of Fibrodysplasia Ossificans Progressiva
CN112545886A (zh)	2015-03-10	2021-03-26	里珍纳龙药品有限公司	无菌刺穿系统和方法
EA039118B1 (ru) *	2015-04-01	2021-12-07	Ридженерон Фармасьютикалз, Инк.	Способ лечения прогрессирующей оссифицирующей фибродисплазии
WO2016168613A1 (en)	2015-04-15	2016-10-20	Regeneron Pharmaceuticals, Inc.	Methods of increasing strength and functionality with gdf8 inhibitors
KR20170140318A (ko)	2015-04-29	2017-12-20	리제너론 파마슈티칼스 인코포레이티드	진행성 골화성 섬유이형성증의 치료
TWI824372B (zh) *	2015-10-12	2023-12-01	美商再生元醫藥公司	活化瘦素受體的抗原結合蛋白
US11542332B2 (en)	2016-03-26	2023-01-03	Bioatla, Inc.	Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US20180008672A1 (en)	2016-07-08	2018-01-11	Regeneron Pharmaceuticals, Inc.	Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
AU2017296040C1 (en)	2016-07-15	2023-06-22	Acceleron Pharma Inc.	Compositions and methods for treating pulmonary hypertension
WO2018067740A1 (en) *	2016-10-05	2018-04-12	Acceleron Pharma, Inc.	Compositions and method for treating kidney disease
US20190240316A1 (en) *	2016-10-17	2019-08-08	Vanderbilt University	Human respiratory syncytial virus antibodies and methods of use therefor
CA3043184A1 (en) *	2016-11-10	2018-05-17	Keros Therapeutics, Inc.	Activin receptor type iia variants and methods of use thereof
CA3055583A1 (en)	2017-05-05	2018-11-08	Regeneron Pharmaceuticals, Inc.	Auto-injector
IL270894B2 (en) *	2017-06-01	2023-04-01	Regeneron Pharma	Human antibodies to bet v 1 and methods of using them
WO2023154672A2 (en) *	2022-02-14	2023-08-17	Ohio University	Methods for regulating muscle performance using fat specific protein 27 (fsp27) compositions
DE102018103302A1 (de) *	2018-02-14	2019-08-14	Noonee Ag	Tragbare Sitzhaltungshilfevorrichtung
IL276921B2 (en) *	2018-03-01	2025-12-01	Regeneron Pharma	Methods for altering body composition
SMT202500283T1 (it)	2018-04-06	2025-09-12	Regeneron Pharma	Un anticorpo agonista del recettore della leptina da utilizzare per aumentare la massa ossea in un soggetto affetto da disfunzione metabolica o ipoleptinemia
SG11202010891SA (en)	2018-06-13	2020-11-27	Regeneron Pharma	A rodent model of fibrodysplasia ossificans progressiva
MX2021005048A (es)	2018-10-31	2021-09-08	Bioatla Inc	Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
CN113195532B (zh) *	2018-12-18	2025-04-11	瑞泽恩制药公司	使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法
CA3142149A1 (en)	2019-05-30	2020-12-03	Acceleron Pharma, Inc.	Actrii-binding proteins and uses thereof
IL294611B1 (en)	2020-01-08	2026-05-01	Regeneron Pharma	Treatment of fibrodysplasia ossificans progressive
KR20210095781A (ko)	2020-01-24	2021-08-03	주식회사 에이프릴바이오	항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
US11945872B2 (en)	2020-02-11	2024-04-02	Regeneron Pharmaceuticals, Inc.	Anti-ACVR1 antibodies and uses thereof
US20230174620A1 (en)	2020-04-28	2023-06-08	Acceleron Pharma Inc.	Actrii proteins and use in treating post-capillary pulmonary hypertension
EP4168038A1 (en)	2020-06-18	2023-04-26	Regeneron Pharmaceuticals, Inc.	Activin a antibody formulations and methods of use thereof
US11897945B2 (en)	2020-07-01	2024-02-13	Regeneron Pharmaceuticals, Inc.	Methods of treating allergy using anti-Bet v 1 antibodies
CN116249713A (zh) *	2020-08-20	2023-06-09	瑞泽恩制药公司	利用激活素a拮抗剂预防和治疗心功能不全和covid-19的方法
CA3197104A1 (en) *	2020-11-11	2022-05-19	Hq Han	Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
US20240366722A1 (en) *	2021-08-16	2024-11-07	Acceleron Pharma Inc.	Compositions and methods for treating renal diseases or conditions
CA3235627A1 (en) *	2021-10-18	2023-04-27	Byomass Inc.	Anti-activin a antibodies, compositions and uses thereof
USD1007676S1 (en)	2021-11-16	2023-12-12	Regeneron Pharmaceuticals, Inc.	Wearable autoinjector
EP4472733A1 (en) *	2022-01-31	2024-12-11	BYOMass Inc.	Myeloproliferative conditions
TWI819587B (zh) *	2022-04-29	2023-10-21	洪慧妤	用於預防癌症所引發的肌少症之組合物及組合物於製造供預防癌症所引發之肌少症食品的用途
JP2025532651A (ja)	2022-09-21	2025-10-01	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	肥満、糖尿病および肝機能障害を処置する方法
WO2024259313A1 (en)	2023-06-16	2024-12-19	Regeneron Pharamceuticals, Inc.	Medical device packaging and related methods
CN116990523A (zh) *	2023-06-30	2023-11-03	重庆医科大学	骨形态蛋白-9作为生物标志物在脓毒血症诊断、预后、疗效评估及治疗中的用途
AU2024347940A1 (en)	2023-09-29	2026-04-30	Peptidream Inc.	Peptide
TW202529831A (zh)	2023-10-02	2025-08-01	美商再生元醫藥公司	藥物遞輸裝置安全系統
US20260000758A1 (en) *	2024-06-28	2026-01-01	Regeneron Pharmaceuticals, Inc.	Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof
WO2026037938A1 (en)	2024-08-16	2026-02-19	Protuoso Pte. Ltd.	Fusion proteins comprising a glp-1 receptor agonist and a myostatin pathway inhibitor
US20260221053A1 (en)	2025-01-29	2026-07-30	Regeneron Pharmaceuticals, Inc.	Drug delivery devices, safety systems, training devices, and methods of use thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en)	1991-06-14	2003-11-26	Genentech, Inc.	HUMANIZED Heregulin ANTIBODy
CA2157577C (en)	1993-03-19	2009-11-17	Se-Jin Lee	Growth differentiation factor-8
US5994618A (en)	1997-02-05	1999-11-30	Johns Hopkins University School Of Medicine	Growth differentiation factor-8 transgenic mice
ES2330062T3 (es)	1998-05-06	2009-12-03	Metamorphix, Inc.	Procedimientos para tratar la diabetes por inhibicion de gdf-8.
EE200200025A (et)	1999-07-20	2003-04-15	Pharmexa A/S	Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto
US7320789B2 (en)	2001-09-26	2008-01-22	Wyeth	Antibody inhibitors of GDF-8 and uses thereof
US7241444B2 (en)	2002-01-18	2007-07-10	Pierre Fabre Medicament	Anti-IGF-IR antibodies and uses thereof
US7261893B2 (en)	2002-10-22	2007-08-28	Wyeth	Neutralizing antibodies against GDF-8 and uses therefor
WO2004108157A2 (en)	2003-06-02	2004-12-16	Wyeth	Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2005066204A2 (en)	2003-12-31	2005-07-21	Schering-Plough Ltd.	Neutralizing epitope-based growth enhancing vaccine
CA2558478A1 (en)	2004-03-02	2005-09-15	Acceleron Pharma Inc.	Alk7 and myostatin inhibitors and uses thereof
US20070178095A1 (en)	2004-03-23	2007-08-02	Eli Lilly And Company	Anti-myostatin antibodies
EP1740946B1 (en)	2004-04-20	2013-11-06	Genmab A/S	Human monoclonal antibodies against cd20
MX2007000976A (es)	2004-08-12	2007-04-10	Wyeth Corp	Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
NZ538097A (en)	2005-02-07	2006-07-28	Ovita Ltd	Method and compositions for improving wound healing
TW200724548A (en)	2005-04-25	2007-07-01	Pfizer	Antibodies to myostatin
US7888486B2 (en)	2005-08-19	2011-02-15	Wyeth Llc	Antagonist antibodies against GDF-8
KR101135220B1 (ko)	2005-10-06	2012-04-24	일라이 릴리 앤드 캄파니	항-마이오스타틴 항체
UA92504C2 (en)	2005-10-12	2010-11-10	Эли Лилли Энд Компани	Anti-myostatin monoclonal antibody
CN112457389A (zh) *	2005-11-23	2021-03-09	阿塞勒隆制药公司	Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
US20070149458A1 (en)	2005-12-06	2007-06-28	Amgen Inc.	Uses of myostatin antagonists
ATE537190T1 (de)	2006-06-02	2011-12-15	Regeneron Pharma	Hochaffine antikörper gegen den humanen il-6- rezeptor
HRP20130320T1 (en)	2006-09-05	2013-05-31	Eli Lilly And Company	Anti-myostatin antibodies
CL2007002567A1 (es)	2006-09-08	2008-02-01	Amgen Inc	Proteinas aisladas de enlace a activina a humana.
TW201718635A (zh)	2007-03-06	2017-06-01	安美基公司	變異之活動素受體多肽及其用途
PE20091163A1 (es)	2007-11-01	2009-08-09	Wyeth Corp	Anticuerpos para gdf8
PL2207775T3 (pl)	2007-11-05	2012-08-31	Novartis Ag	Pochodne 4-benzyloamino-1-karboksyacylo-piperydyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic
DK3750552T5 (da)	2008-08-14	2024-08-26	Acceleron Pharma Inc	Gdf-fælder
PE20150680A1 (es) *	2008-11-26	2015-05-16	Amgen Inc	Variantes de polipeptidos receptores de activina iib y aplicaciones de estos
TW201029662A (en)	2008-12-19	2010-08-16	Glaxo Group Ltd	Novel antigen binding proteins
ES2655877T3 (es)	2009-04-27	2018-02-22	Novartis Ag	Composiciones y métodos para aumentar el crecimiento muscular
TWI507525B (zh)	2009-06-26	2015-11-11	Regeneron Pharma	具天然免疫球蛋白形式之易分離的雙專一性抗體
ES2658292T3 (es)	2009-11-17	2018-03-09	Acceleron Pharma, Inc.	Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
JO3340B1 (ar)	2010-05-26	2019-03-13	Regeneron Pharma	مضادات حيوية لـعامل تمايز النمو 8 البشري
CA2817008A1 (en)	2010-11-08	2012-05-18	Acceleron Pharma Inc.	Actriia binding agents and uses thereof
SMT201800092T1 (it)	2011-11-14	2018-03-08	Regeneron Pharma	Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
GR1007832B (el)	2011-11-21	2013-02-14	Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων,	Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
MY177331A (en)	2012-06-15	2020-09-12	Pfizer	Improved antagonist antibodies against gdf-8 and uses therefor
KR20150136061A (ko)	2013-02-01	2015-12-04	산타 마리아 바이오테라퓨틱스, 인코포레이티드	대상에 항-액티빈-a 화합물의 투여
TWI655207B (zh)	2013-07-30	2019-04-01	再生元醫藥公司	抗活化素ａ之抗體及其用途
US20160075772A1 (en)	2014-09-12	2016-03-17	Regeneron Pharmaceuticals, Inc.	Treatment of Fibrodysplasia Ossificans Progressiva
WO2016168613A1 (en)	2015-04-15	2016-10-20	Regeneron Pharmaceuticals, Inc.	Methods of increasing strength and functionality with gdf8 inhibitors
IL276921B2 (en) *	2018-03-01	2025-12-01	Regeneron Pharma	Methods for altering body composition

2014
- 2014-07-28 TW TW103125622A patent/TWI655207B/zh active
- 2014-07-28 TW TW107147614A patent/TW201920262A/zh unknown
- 2014-07-30 KR KR1020217033330A patent/KR102440044B1/ko active Active
- 2014-07-30 EP EP22171329.0A patent/EP4062937A1/en active Pending
- 2014-07-30 CA CA2920071A patent/CA2920071C/en active Active
- 2014-07-30 PT PT147504211T patent/PT3027209T/pt unknown
- 2014-07-30 MX MX2016001394A patent/MX371498B/es active IP Right Grant
- 2014-07-30 BR BR112016002164-9A patent/BR112016002164B1/pt active IP Right Grant
- 2014-07-30 ES ES14750421T patent/ES2827673T3/es active Active
- 2014-07-30 PH PH1/2016/500182A patent/PH12016500182B1/en unknown
- 2014-07-30 AU AU2014296243A patent/AU2014296243B2/en active Active
- 2014-07-30 MX MX2020001201A patent/MX379446B/es unknown
- 2014-07-30 CN CN202111054074.XA patent/CN113845594A/zh active Pending
- 2014-07-30 WO PCT/US2014/048957 patent/WO2015017576A1/en not_active Ceased
- 2014-07-30 EA EA201690243A patent/EA037926B1/ru unknown
- 2014-07-30 EP EP20176858.7A patent/EP3730151A1/en active Pending
- 2014-07-30 JP JP2016531870A patent/JP6581085B2/ja active Active
- 2014-07-30 KR KR1020167005280A patent/KR102315694B1/ko active Active
- 2014-07-30 RS RS20201414A patent/RS61124B1/sr unknown
- 2014-07-30 DK DK14750421.1T patent/DK3027209T3/da active
- 2014-07-30 LT LTEP14750421.1T patent/LT3027209T/lt unknown
- 2014-07-30 SM SM20200643T patent/SMT202000643T1/it unknown
- 2014-07-30 SG SG11201600731WA patent/SG11201600731WA/en unknown
- 2014-07-30 SI SI201431693T patent/SI3027209T1/sl unknown
- 2014-07-30 EP EP14750421.1A patent/EP3027209B1/en active Active
- 2014-07-30 US US14/447,444 patent/US9718881B2/en active Active
- 2014-07-30 UY UY35682A patent/UY35682A/es active IP Right Grant
- 2014-07-30 HR HRP20201729TT patent/HRP20201729T1/hr unknown
- 2014-07-30 HU HUE14750421A patent/HUE052518T2/hu unknown
- 2014-07-30 EP EP22171327.4A patent/EP4059520A1/en active Pending
- 2014-07-30 CN CN201480049484.7A patent/CN105592858B/zh active Active
2016
- 2016-01-28 IL IL24382216A patent/IL243822B/en active IP Right Grant
- 2016-01-29 CL CL2016000251A patent/CL2016000251A1/es unknown
- 2016-02-25 ZA ZA2016/01294A patent/ZA201601294B/en unknown
2017
- 2017-06-29 US US15/637,867 patent/US10526403B2/en active Active
2019
- 2019-08-28 JP JP2019155139A patent/JP6923602B2/ja active Active
- 2019-10-27 IL IL270218A patent/IL270218B/en active IP Right Grant
2020
- 2020-02-07 AU AU2020200892A patent/AU2020200892B2/en active Active
- 2020-07-10 US US16/926,481 patent/US20210163583A1/en not_active Abandoned
- 2020-12-01 CY CY20201101138T patent/CY1123788T1/el unknown
2021
- 2021-07-28 JP JP2021122976A patent/JP7440464B2/ja active Active
2022
- 2022-06-29 JP JP2022104218A patent/JP7496387B2/ja active Active
- 2022-08-09 JP JP2022126761A patent/JP7589200B2/ja active Active
- 2022-11-28 US US18/059,315 patent/US20230312699A1/en active Pending
2024
- 2024-11-12 JP JP2024197067A patent/JP2025024066A/ja active Pending

Also Published As

Publication number	Publication date
IL270218B (en)	2021-01-31
MX2020001201A (es)	2021-01-28
EA201690243A1 (ru)	2016-06-30
JP7440464B2 (ja)	2024-02-28
BR112016002164A2 (pt)	2017-09-12
DK3027209T3 (da)	2020-11-02
JP2025024066A (ja)	2025-02-19
AU2020200892B2 (en)	2022-03-31
KR102440044B1 (ko)	2022-09-06
CN105592858B (zh)	2021-10-01
WO2015017576A1 (en)	2015-02-05
HUE052518T2 (hu)	2021-05-28
JP2022160619A (ja)	2022-10-19
US20150037339A1 (en)	2015-02-05
EP3027209A1 (en)	2016-06-08
AU2020200892A1 (en)	2020-03-05
US20230312699A1 (en)	2023-10-05
IL243822B (en)	2019-11-28
UY35682A (es)	2015-02-27
JP2016528232A (ja)	2016-09-15
EP4062937A1 (en)	2022-09-28
TWI655207B (zh)	2019-04-01
CN105592858A (zh)	2016-05-18
ES2827673T3 (es)	2021-05-24
MX2016001394A (es)	2016-08-03
HRP20201729T1 (hr)	2020-12-25
RS61124B1 (sr)	2020-12-31
LT3027209T (lt)	2020-12-28
TW201602133A (zh)	2016-01-16
PH12016500182A1 (en)	2016-04-25
JP2021176887A (ja)	2021-11-11
ZA201601294B (en)	2017-05-31
EP4059520A1 (en)	2022-09-21
CA2920071C (en)	2023-05-23
KR20210129253A (ko)	2021-10-27
IL243822A0 (en)	2016-04-21
EP3730151A1 (en)	2020-10-28
CA2920071A1 (en)	2015-02-05
KR20160030581A (ko)	2016-03-18
SG11201600731WA (en)	2016-02-26
US10526403B2 (en)	2020-01-07
AU2014296243B2 (en)	2019-11-21
NZ754959A (en)	2022-03-25
EA037926B1 (ru)	2021-06-08
CL2016000251A1 (es)	2017-07-14
KR102315694B1 (ko)	2021-10-21
AU2014296243A1 (en)	2016-03-03
US9718881B2 (en)	2017-08-01
TW201920262A (zh)	2019-06-01
SI3027209T1 (sl)	2020-11-30
JP7496387B2 (ja)	2024-06-06
MX371498B (es)	2020-01-31
EP3027209B1 (en)	2020-09-02
JP2022130593A (ja)	2022-09-06
BR112016002164B1 (pt)	2023-12-19
US20210163583A1 (en)	2021-06-03
CN113845594A (zh)	2021-12-28
NZ716854A (en)	2022-03-25
JP7589200B2 (ja)	2024-11-25
US20180155416A1 (en)	2018-06-07
MX379446B (es)	2025-03-10
PT3027209T (pt)	2020-10-22
PH12016500182B1 (en)	2024-04-12
CY1123788T1 (el)	2022-03-24
HK1225322A1 (en)	2017-09-08
JP6923602B2 (ja)	2021-08-25
JP6581085B2 (ja)	2019-09-25
JP2020011965A (ja)	2020-01-23

Publication	Publication Date	Title
IL261743B (en)	2020-11-30	and their uses 33–il antibodies against
IL261547B (en)	2019-12-31	Antibodies against pesidine and their uses
ZA201601294B (en)	2017-05-31	Anti-activin a antibodies and uses thereof
IL245040A0 (en)	2016-05-31	Antibodies against pdgfr-beta and their uses
IL243974B (en)	2018-06-28	Antibodies against –prlr and uses
ZA201508896B (en)	2019-06-26	Anti-c10orf54 antibodies and uses thereof
SG10201709715RA (en)	2017-12-28	Anti-b7-h5 antibodies and their uses
SG11201509116VA (en)	2015-12-30	Anti-tweakr antibodies and uses thereof
EP2953970A4 (en)	2016-06-29	TRANSTYRETIN ANTIBODIES AND USES THEREOF
HUE049446T2 (hu)	2020-09-28	Anti-FCRH5 antitestek
GB201322583D0 (en)	2014-02-05	Antibodies
IL244043A0 (en)	2016-04-21	Antibodies
GB201308658D0 (en)	2013-06-26	Antibodies
GB201315486D0 (en)	2013-10-16	Antibodies
GB201300706D0 (en)	2013-02-27	Antibody
IL245488B (en)	2020-03-31	Anti- ccl17 antibodies
GB201318283D0 (en)	2013-11-27	Antibodies